(PDF) EGFR Mutation Detection in ctDNA From NSCLC Patient

EGFR Mutation Detection in ctDNA From NSCLC Patient Plasma: A Cross-Platform Comparison of Leading Technologies to Support the Clinical Development of AZD9291

Lung Cancer - Netherlands

doi 10.1016/j.lungcan.2015.10.004

Full Text

Open PDF

Abstract

Available in full text

Date

December 1, 2015

Authors

Publisher

Elsevier BV

Related search

P3.02b-012 Longitudinal Monitoring of ctDNA EGFR Mutation Burden From Urine Correlates With Patient Response to EGFR TKIs: A Case Series

Journal of Thoracic Oncology

English

Comparison of EGFR-TKI and Chemotherapy in the First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC

Neoplasma

Cancer Research

2013

English

Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M

English

P3.04-02 Early Plasma ctDNA Response Anticipates Clinical Response to First-Line Immunotherapy in Advanced NSCLC

Journal of Thoracic Oncology

English

Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC

Lung Cancer Management

2020

English

P061 Real Clinical Practice of Using Immunotherapy in NSCLC Patients With EGFR Mutation

Journal of Thoracic Oncology

English

P3.01-80 Retrospective Analysis of the Impact of EGFR T790M Mutation Detection by Re-Biopsy in Patients With NSCLC Harboring EGFR Mutations.

Journal of Thoracic Oncology

English

P2.01-128 Low Positivity Rate in T790M Detection With ctDNA in NSCLC and Post EGFR-TKI Progression – Timing or Sensitivity?

Journal of Thoracic Oncology

English

Clinical Evaluation of the Utility of a Liquid Biopsy (Circulating Tumoral Cells and ctDNA) to Determine the Mutational Profile (EGFR, KRAS, ALK, ROS1 and BRAF) in Advanced NSCLC Patients

English

Amanote Research

EGFR Mutation Detection in ctDNA From NSCLC Patient Plasma: A Cross-Platform Comparison of Leading Technologies to Support the Clinical Development of AZD9291

Lung Cancer - Netherlands

doi 10.1016/j.lungcan.2015.10.004

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

P3.02b-012 Longitudinal Monitoring of ctDNA EGFR Mutation Burden From Urine Correlates With Patient Response to EGFR TKIs: A Case Series

Comparison of EGFR-TKI and Chemotherapy in the First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC

Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M

P3.04-02 Early Plasma ctDNA Response Anticipates Clinical Response to First-Line Immunotherapy in Advanced NSCLC

Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC

P061 Real Clinical Practice of Using Immunotherapy in NSCLC Patients With EGFR Mutation

P3.01-80 Retrospective Analysis of the Impact of EGFR T790M Mutation Detection by Re-Biopsy in Patients With NSCLC Harboring EGFR Mutations.

P2.01-128 Low Positivity Rate in T790M Detection With ctDNA in NSCLC and Post EGFR-TKI Progression – Timing or Sensitivity?

Clinical Evaluation of the Utility of a Liquid Biopsy (Circulating Tumoral Cells and ctDNA) to Determine the Mutational Profile (EGFR, KRAS, ALK, ROS1 and BRAF) in Advanced NSCLC Patients